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Abstract
Bovine rhodopsin is the prototypical G protein coupled receptor (GPCR). It was the first GPCR to be obtained in quantity and studied in
detail. It is also the first GPCR for which detailed three dimensional structural information has been obtained. Reviewed here are the
experiments leading up to the high resolution structure determination of rhodopsin and the most recent structural information on the
activation and stability of this integral membrane protein.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
G protein coupled receptors (GPCR) represent a very
large family of integral membrane proteins involved in a
wide variety of signal transduction, largely at the plasma
membranes of cells. Estimates vary, but as many as 1000
such receptors may exist, controlling vision, olfaction, taste,
and many specific cellular functions through hormones and
other signals.
Vision is one of the ‘‘senses’’ mediated by GPCRs. Two
distinct kinds of cells provide the extant sensitivity to the
spectrum of visible light of higher animals. Rod cells in the
retina are exquisitely sensitive to low levels of light, acting
effectively as single photon counters. These cells provide
sensitivity to light in black and white. The other major cell
type in the retina that is sensitive to light is the cone cell.
Cone cells are perhaps 100 times less sensitive to light than
rod cells, but provide color vision. In human retinas, three
cone subtypes are known, each sensitive to different band
widths of visible light.
The retinal rod photoreceptor is a highly polarized, post-
mitotic cell which is involved in signal transduction. The
rod cells in vertebrate and invertebrate retinas are part of a
complex array of neural and epithelial cells that are respon-
sible for the capture of light and the transmission of the
resulting nerve impulse to the brain. Rod cells make vision
at low light levels possible, and the degeneration of these
cells leads to night blindness. These rod cells are divided
morphologically into an inner segment and an outer seg-
ment. The outer segment of the rod cell encloses a stack of
densely packed, closed, flattened membrane sacs referred to
as disks, which are stacked along the long dimension of the
outer segment. This stack of disks within the rod outer
segment (ROS) undergoes dynamic renewal. The disks are
formed from evaginations of the ROS plasma membrane at
the base of the ROS and progressively move up the outer
segment as additional new disks are formed. Old disks at the
apical tip of the rod are shed and then phagocytosed by the
overlying pigmented epithelium. Thus, the outer segment is
in a constant state of degradation and renewal [1,2]. In
vertebrates, the transit of disks from the base to the tip of the
outer segment requires approximately 10 days.
The ROS membranes contain lipids and proteins, in
approximately equal amounts by weight [3,4]. Phospholi-
pids represent almost 90 mol% of the total ROS lipids,
while cholesterol accounts for less than 10 mol% on average
[3,5]. Cholesterol is not uniformly distributed among the
ROS disk membranes, however. Newly formed disks are
high in cholesterol content, similar to the plasma membrane
from which they form. As the disks age, the cholesterol
content decreases, until it reaches 5 mol% or less in the old
disks [6,7]. The change in cholesterol content with age of
the disk membrane is related to a modulation of activity of
rhodopsin in that disk membrane. High cholesterol leads to
inhibition of receptor function [8,9].
0005-2736/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0005 -2736 (02 )00568 -0
* Corresponding author. Tel.: +1-860-486-4363; fax: +1-860-455-
4331/0179.
E-mail address: yeagle@uconnvm.uconn.edu (P.L. Yeagle).
www.bba-direct.com
Biochimica et Biophysica Acta 1565 (2002) 183–195
Cone cells also contain GPCRs sensitive to light. These
GPCRs are found in evaginations of the plasma membrane
of the outer segment that resemble the stacked disks of the
rod cell except that they are part of a continuous plasma
membrane. Interestingly, because the cone rhodopsins are in
the plasma membrane, they are in a high cholesterol
environment and cholesterol is known to inhibit receptor
function. This difference in morphology from the rod cell
may explain the much higher sensitivity of the rod cell to
light, because in rod disks, separate from the plasma
membrane, membrane cholesterol is low and rhodopsin
function is greatly enhanced.
Glycerolipid constituents are not constrained to remain
with the disks into which they were initially assembled;
rather, individual lipid classes have distinct turnover rates
which are considerably more rapid than those of the
membrane proteins [10–16]. Phospholipid fatty acid
composition among disks is also a function of disk age
[17].
In striking contrast to the complexity of the ROS lipid
molecular species composition [17,18], rhodopsin (the vis-
ual pigment) accounts for about 95% of the total ROS
membrane protein [19,20]. Rhodopsin, once assembled into
a disk, remains associated with that disk throughout its
lifetime in the ROS. Thus, the turnover of rhodopsin
parallels the basal-to-apical transit time of the disks in the
ROS, and the relative location of a disk along the length of
the ROS reflects the age of its protein constituents (i.e., the
basal-most disks contain the most recently synthesized
proteins) [21,22]. The binding of transducin by rhodopsin
is also a function of disk age [23].
When light strikes the ROS and is absorbed by the
photopigment, rhodopsin goes through a series of spectrally
defined intermediates. The transition of metarhodopsin I to
metarhodopsin II (Meta II, the active form of the receptor)
stimulates the binding of the G protein, transducin. Trans-
ducin becomes activated and the a subunit of transducin
initiates the cGMP cascade [24] by binding to the phospho-
diesterase, and culminating in the hydrolysis of cGMP.
Reduction in cGMP levels leads to closure of the plasma
membrane Na+ channels, which results in a hyperpolariza-
tion of the plasma membrane that is transmitted to the
synapse at the base of the rod cell.
Rhodopsin is a member of a large family of GPCRs. All
of these receptors couple to heterotrimeric G proteins as the
means to convert an extracellular signal into an intracellular
signal. Many of these receptors bind ligands from the cell
exterior, which induce a conformational change in the
cytoplasmic face of the receptor, enabling binding of the
G protein. When the G protein binds to an active receptor,
an exchange of GTP for GDP on the a subunit occurs and
the a subunit separates from the hg subunit. In some
systems, both the a subunit and the hg complex can
function in signaling. Upon activation, the a subunit of
the G protein can modulate the activity of a target protein,
often an enzyme. The a subunit is itself a GTPase, and thus
with time, the GTP bound to the a subunit is hydrolyzed.
The GDP-bound form of the a subunit is inactive and can
reassociate with the hg complex to recycle the G protein.
Rhodopsin is ultimately responsible for the initiation of
visual signal transduction. The ligand for rhodopsin is 11-
cis retinal, which is covalently bound to the receptor in
the dark-adapted state. The retinal is photosensitive and
confers on the receptor the sensitivity to light. Photo-
activation to all-trans retinal provides the trigger to a
conformational change in the receptor to the active form
(Meta II). The all-trans retinal is then expelled from the
receptor and is cycled, through the adjacent pigmented
epithelium, to 11-cis retinal, ready to recombine with a
bleached opsin (rhodopsin without retinal) to re-form
rhodopsin.
Rhodopsin is the most intensively studied member of
the GPCR family because it is the only member that is
naturally present in high abundance in biological tissues.
Earlier reviews have been published (for example, see Ref.
[25]). After methods were developed to isolate ROS disk
membranes [26], relatively large amounts of natural mem-
brane containing predominantly one membrane protein
could be obtained for study. Subsequently, the purification
of rhodopsin on an affinity column in detergent was
reported [27] and reconstitution of purified rhodopsin into
membranes of defined lipid content could be achieved
[28,29].
Rhodopsin is also the first (and only) GPCR for which
high-resolution three-dimensional structural information is
available. A crystal structure of bovine rhodopsin was pub-
lished in 2000 [30] (R.E. Stenkamp et al., this issue) and a
second structure obtained by an alternative approach, was
published in 2001 [31]. This review will explore the early
literature leading up to the recent structure determinations
and will then focus on the most recent structural information
which has revealed for the first time the conformational
change that occurs upon receptor activation.
2. Early structure results
The first data on the three-dimensional structure of
bovine rhodopsin came from circular dichroism (CD) stud-
ies of sonicated disks [32] and of the purified protein
[33,34]. The CD data were analyzed according to secondary
structure content and that analysis was consistent with a
structure containing a bundle of seven transmembrane
helices [35]. Data also suggested that when light was
absorbed by rhodopsin, movement occurred within the
bundle of helices. Later, FTIR data also provided informa-
tion on the helices of rhodopsin [36].
The next step in understanding the three-dimensional
structure of bovine rhodopsin was achieved with the pub-
lication of the primary sequence [37,38]. The primary
sequence is represented in Fig. 1, along with the hydropathy
plot. This analysis suggests several hydrophobic segments
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in the protein. In particular, six hydrophobic segments are
relatively obvious from such a plot, consistent with six of
the seven putative transmembrane helices. As is now
known, the seventh helix is quite polar in the middle with
one lysine , one serine and one threonine, and thus does not
show well in the hydropathy analysis.
Fig. 1. Top: schematic representation of the primary sequence of rhodopsin. Bottom: hydropathy plots of the sequence of rhodopsin.
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The next milestone in the development of structural
information for rhodopsin came about a decade later with
the publication of a low-resolution structural analysis from
two-dimensional crystals of bovine rhodopsin [39]. Electron
density maps suggested positions for most of the putative
transmembrane helices and these helices were assigned using
a model developed by Baldwin et al. [40]. Baldwin per-
formed an extensive analysis of the available sequences of
GPCRs (with the advent of modern molecular biology, the
number of GPCR sequences had increased from one in 1983
to several dozen in the early 1990s). She identified a number
of conserved residues in the transmembrane region of the
protein. She developed a useful nomenclature of labeling
these residues and some suggested rules for the likely
disposition of such conserved residues within the structure.
This was followed by a low-resolution three-dimensional
structure for bovine rhodopsin in which, for the first time, one
could see the bundle of transmembrane helices and trace most
of them through the electron density. One of the first
observations from such analysis was that, contrary to many
expectations, the structure of bovine rhodopsin was not the
same as bacteriorhodopsin [41]. The packing of the helices
differed between the two photosensitive proteins. This was
made more obvious by studies on frog rhodopsin [42] and
squid rhodopsin [43], which showed strong similarity with
bovine rhodopsin and significant differences from bacterio-
rhodopsin. These observations called into question some of
the early models for bovine rhodopsin built on the template of
bacteriorhodopsin. However, more recent models using some
limited experimental data and the models and principles
enunciated by Baldwin proved to be more accurate [44].
As details emerged about the packing of the helices in
rhodopsin, several distinctive features were identified. One
feature is the tilt of helix 3. Helix 3 is the most severely
tilted helix of the bundle in the dark-adapted state structure
of rhodopsin. At the other extreme, helices 4, 6 and 7 were
suggested to be the closest to perpendicular to the mem-
brane surface. These features have survived into the most
recent three-dimensional structure determinations for rho-
dopsin, as will be seen below.
3. Studies on proximity of sites within the protein
Several different methods were developed in the 1990s to
measure distances between discrete sites on the protein, or
to probe close contacts within the rhodopsin structure. Many
of these studies employed one of two different methods.
One method is site-directed spin labeling, developed as a
collaboration between the laboratories of Hubbell and
Khorana for use on bovine rhodopsin. The other, described
in detail by Oprian et al., explores close contacts between
helices with engineered disulfide bonds.
Site-directed spin labeling has proven a powerful method
to obtain long-range distances between specific sites in the
intact protein [45]. Using mutagenesis, one can control the
availability of cysteines for reaction with spin label probes.
For example, one can make a cysteine-less protein and then
reintroduce two cysteines at specific positions. Labeling this
protein with spin labels produces two labeled sites. The
dipolar interaction between the two sites can be measured
and since the dipolar interaction is distance-dependent, the
magnitude of that dipolar interaction can be interpreted in
terms of a distance in angstroms between the labels. Dis-
tances between about 5 and 25 A˚ can be determined by this
method.
The laboratories of Hubbell and of Khorana have collabo-
rated to create a wealth of distance data for rhodopsin using
this technique [46–61]. These experiments have both pro-
vided data on distances between specific sites in dark-adapted
rhodopsin and also have provided data on the transient state
of metarhodopsin II, the activated state of rhodopsin. From
these data, they concluded that movements in helix 3 and
helix 6 are among the conformational changes that occur
when rhodopsin converts to metarhodopsin II. Some of the
distance information obtained for rhodopsin by this technique
is summarized in Table 1.
The spin label experiments also provide indirect informa-
tion on secondary structure. Periodicities in the EPR spectra
from labels at sequential positions in the sequence point to the
occurrence of a helix, in some cases. With this kind of
experiment, they were able to locate the carboxyl end of
helix 5, for example [48]. These experiments also reveal
information about the exposure of sites to the aqueous phase
and about dynamics of the polypeptide chain at the spin label
position.
Engineered disulfide bonds have provided considerable
information about contacts between helices in the trans-
membrane helical bundle of rhodopsin. Much work in this
area has come from Yu et al. [62]. Putative contact points
Table 1
Experimental long-range constraints for rhodopsin
R* (A˚) R (A˚)
V139C_K248C 23–25 12–14
V139C_E249C 15–20 15–20
V139C_V250C 12–14 15–20
V139C_T251C 23–25 12–14
V139C_R252C 23–25 15–20
H65C_C31 [49,50,168] 12–15 7–10
C140_S338 [169] 15–21
V204C_F276C [62] 2–5 2–5
I251_V138 [68] < 13
C140_C222 [67] >7 2–5
C140_Q225C 2–5 2–5
K245C_Q312C >7 2–5
R135C_V250C >7 2–5
K245C_S338C [56] 2–5 2–5
S338C_T242C [53] >7 2–5
Y136C_C222 >7 2–5
Y136C_Q225C 2–5 2–5
Interhelical distances [40] X
Helix assignment of Baldwin [145]
Where R* is Meta II, and R is rhodopsin (not activated).
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are probed by introducing cysteines at key positions in the
protein and looking for the formation of disulfide bonds
between those two cysteines. This approach has produced a
number of contact points within rhodopsin and some of
these data are summarized in Table 1 [63–65].
These experiments have yielded important information
on the conformational change from dark-adapted rhodopsin
to metarhodopsin II. In some cases, the disulfide bonds
inhibit the change in conformation suggesting that those
contact points are no longer in contact in metarhodopsin II.
In other cases, the presence of the disulfide bonds does not
inhibit the formation of metarhodopsin II, and thus indicated
that those points of contact are present in both the dark-
adapted state and the active state of the receptor [66,67].
The success of these disulfide experiments depended upon
another important observation about the structure of rhodop-
sin. Oprian et al. were able to express rhodopsin in two
pieces, each piece containing two or more transmembrane
helices. For example, one of the two pieces contained four of
the transmembrane helices of rhodopsin and the correspond-
ing linking loops, and the other piece contained the remaining
three of the transmembrane helices and the connecting links.
These researchers noted that the separate, co-expression of
these pieces of rhodopsin led to the formation of pigment;
that is a protein that incorporated the ligand, retinal, even
though the two pieces were not covalently linked. By some
process after expression, the two pieces came together in the
membrane in a native-like conformation. This work suggests
considerable stability within the helical bundle that will be
discussed later in this article.
If a metal ion binding site can be engineered between
two or more helices with residues from each of the helices
contributing ligands to the metal ion, then one can identify
a close approach of those helices. Such an experiment was
performed in rhodopsin, which showed contact between
helices 3 and 6. Furthermore, this contact was apparently
broken upon activation of the receptor [68].
4. Retinal in rhodopsin
The ligand, retinal, has been studied extensively in rho-
dopsin. It is beyond this review to consider the whole of this
body of work. However, among this important body of work
are structural studies of the retinal in the protein [69–78].
These studies suggested interactions between specific amino
acids in the rhodopsin structure and the retinal chromophore,
demonstrated the protonated Schiff base the retinal forms
with lys296, and provided detailed information on the ori-
entation and location of the retinal in rhodopsin.
5. Three-dimensional structure of rhodopsin
The X-ray crystal structure of rhodopsin [30] is
described in detail elsewhere in this volume. However,
the importance of this contribution should be emphasized.
This is the first three-dimensional structure of any member
of the GPCR family. It was possible to see for the first time
details of the organization of the transmembrane helical
bundle, the location of retinal in the structure, the intra-
diskal (extracellular) face, the palmitoylation of the protein,
and the closure of the intradiskal face over the retinal,
locking it into the structure of the protein. Missing from
this structure are details of the cytoplasmic face of the
protein.
Several years before the publication of this structure,
another approach to the structure of rhodopsin was begun
[79]. This approach, to be described below, ultimately led
to the publication of a second structure of rhodopsin, in
excellent agreement with the crystal structure, but provid-
ing greater detail in the cytoplasmic face of the protein. A
somewhat simpler version of this method has been used to
determine, in part, the backbone fold for other proteins
[80–82]. This approach circumvents the need to have
crystals and is applicable to structure determination for
other GPCRs and perhaps other membrane proteins as well.
A growing body of data suggests that solution structures of
peptides derived from some classes of proteins retain the
secondary structure of the parent protein because of the
dominance in a-helices and turns of short-range interactions
[83] that can be captured in peptides. Studies on segments of
soluble proteins forming a-helices show that peptides con-
taining these sequences form a-helix in almost every case
under some solution conditions [84–93]. Peptides represent-
ing segments that are turns in the native protein also show
turns as peptides in solution [89,92,94–100]. In some cases,
the entire sequence of a helical bundle protein has been
incorporated in a series of peptides spanning that sequence
and the individual peptides have reported the secondary
structure of much of the native protein with fidelity
[97,101–104].
The use of peptides to determine the secondary structure
of membrane proteins is becoming widely accepted. Recent
studies on transmembrane proteins, including bacteriorho-
dopsin, rhodopsin, tachykinin receptor, PTH receptor,
angiotensin II receptor, a-factor receptor, potassium chan-
nels, and glycophorin, showed that peptides from trans-
membrane helices formed a-helices independently from the
rest of the protein [93,105–115] and peptides from turns
show turns independently of the remainder of the protein
[116–122].
The issue of independent stabilization of membrane
protein domains has been investigated. For example,
glycophorin is a membrane protein that can be cleaved
into fragments that retain the secondary structure of the
native protein after separation [123]. Both rhodopsin [35]
(as described earlier) and the Na+ K+ ATPase [124] are
membrane proteins for which proteolytic fragments retain
structures characteristic of the native protein. Yu et al.
[62] have shown that rhodopsin can be expressed as
fragments that spontaneously assemble after expression
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into a functional unit in the membrane. Similar studies
have been done on the a-factor receptor [125]. The
cytoplasmic loops of rhodopsin have functions separate
from the remainder of the protein [121,126,127], and
have structure as well [79,119].
It can therefore be hypothesized that the intrinsic
structures of peptides containing the amino acid sequences
for turns or for transmembrane helices of membrane
proteins built of helical bundles will be the same that
those sequences adopt in the native protein. This hypoth-
esis could provide access to important structural informa-
tion for a transmembrane protein that may be available
from no other approach.
6. Test of alternative approach to membrane protein
structure: bacteriorhodopsin
This hypothesis was tested for membrane proteins using
bacteriorhodopsin, a protein whose structure was already
known. The structure of bacteriorhodopsin consists of a
bundle of seven transmembrane helices connected by turns.
Hunt et al. [93] have found that the transmembrane helices of
this protein are independently stable folding units and thus
can be considered protein domains [105]. Several X-ray
crystal structures are available for this membrane protein
[128–131].
A series of peptides were designed for bacteriorhodopsin
[132]. Each peptide was designed to encompass either a
transmembrane helix of the protein or a turn. Peptides
containing a turn also included some of the helices (one to
two turns) that connect to the turn on both sides. Furthermore,
each peptide was designed to overlap each of its neighbors in
the series by 10 amino acids. The overlap was necessary
because structures of peptides in solution typically show
disordered termini. To obtain structural information on the
entire sequence thus necessitated a design in which the
disordered ends of each of the peptides could be ignored.
The structures of these peptides in solution were deter-
mined by two-dimensional homonuclear 1H NMR as
described in detail previously [117,132]. Most of the pep-
tides in this set from bacteriorhodopsin were hydrophobic
and not soluble in water. All peptides in the series were
soluble in DMSO except for the peptide corresponding to
helix G, which was not soluble in DMSO or in chloroform/
methanol solutions. Previous work had shown that helix G
was not stable in detergent micelles either [93]. DMSO was
chosen as a solvent that could be used in common for the 12
of the 13 peptides that were soluble.
The solution structure of each soluble peptide was
determined using 1H nuclear magnetic resonance (NMR).
Each of the 12 peptides exhibited one family of structures in
solution. Peptides corresponding to helices A, B, C, D, E,
and F of bacteriorhodopsin formed helices in solution that
agreed well with the crystal structure [132]. The peptides
corresponding to all six turns from bacteriorhodopsin form
turns with the same residues in both the crystal structure and
the peptide [132]. Most of these peptide structures super-
impose on the crystal structure with an rmsd less than 2.5,
indicating that the structures in the peptides are the same as
in the crystal structure (given the limited number of con-
straints normally available from modest-sized peptides in
solution) [132]. For comparison, the overall backbone rmsd
between two crystal structures of bacteriorhodopsin (2BRD
and 1AP9) is about 2.3. High B factors from the loops in the
crystal structures complicate comparisons; nevertheless, the
residues that define the turns in the crystal structures and in
the peptides are the same.
Fig. 2. Structure of bacteriorhodopsin obtained as described in the text and in Ref. [132]. The structure obtained from the NMR data is in red (1 lom) and the
structure from X-ray crystallography (2brd) is in green.
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Exploiting the overlap of adjacent peptides, a continuous
construct of all the peptides can be made by superimposing
the backbone atoms of the overlapping regions. All avail-
able experimental distance constraints were then written on
this construct as described below, including 2438 distance
range constraints and 75 angle constraints. Some interhelical
distance constraints were used in this structure determina-
tion to help in organizing the helical bundle. These con-
straints can be obtained from more than one source: low-
resolution diffraction studies of two-dimensional crystals,
solid state NMR experiments (rotational resonance), cys-
teine scanning (disulfide bond formation), dipolar interac-
tions between spin labels, fluorescence energy transfer
measurements, engineering of metal binding sites, or com-
plementary mutagenesis experiments.
Simulated annealing is used to optimize the conformation
of the protein with respect to all the experimental constraints
simultaneously. The result is shown in Fig. 2 [132]. Fig. 2
also shows an overlay of this structure on a previously
determined structure of bacteriorhodopsin. This comparison
shows considerable agreement between the two structures
determined by different methods (rmsd 2.9).
These results suggest that considerable structural infor-
mation can be obtained from the segmented approach
described in this work for transmembrane proteins built
around helical bundles. This method does not replace X-ray
crystallography, but is expected to be useful in the absence
of X-ray crystallography.
7. Structure of dark-adapted bovine rhodopsin by NMR
The successful test of this novel approach to structure on
bacteriorhodopsin encouraged the application of the
approach to a new membrane protein, bovine rhodopsin. As
stated earlier, the recent X-ray crystal structure of rhodopsin
[30] provided a high-resolution structure of the transmem-
brane domain of the dark-adapted (not activated) state of this
receptor, but did not provide the structure of the cytoplasmic
face which couples to the G protein in signal transduction. By
applying the novel approach described here to rhodopsin,
new information on the structure of the cytoplasmic face of
this receptor was obtained and it was possible to map, at least
in part, the G protein binding site on this structure.
A series of overlapping peptides spanning the rhodopsin
sequence was synthesized. Each peptide was designed to
represent either a transmembrane helix of the protein or a
turn. Each peptide was designed to overlap each of its
neighbors in the series because structures of peptides in
solution typically show disordered termini. To obtain secon-
dary structure from the entire sequence thus necessitated a
design in which the disordered ends of each of the peptides
could be ignored. Solution structures for all the peptides were
determined by two-dimensional homonuclear 1H NMR as
described in part previously [79,119,133]. Structures were
determined in water or in DMSO for water-insoluble peptides
(as described above, structures of the water-insoluble helices
and loops of bacteriorhodopsin in DMSO superimposed well
Fig. 3. Three-dimensional structure of rhodopsin in stereo, obtained from NMR data as described in the text (1jfp).
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on the crystal structure). Most peptides show well-defined
structure except at the extreme termini. Peptides from helices
showed helices in agreement with the X-ray crystal structure
of rhodopsin [111,112,134]. For most of the overlapping
sequences, both peptides were helical in the overlapping
sequence. Superposition of those helical overlaps [112]
linked the segments into a construct corresponding to the
entire sequence of rhodopsin. To K296 11-cis retinal was
added.
Experimental distance constraints were written into the
mol2 file for this construct in SYBYL (Tripos). 3030 short-
range NOE-derived distance constraints were available from
the NMR structure determinations on the individual peptides.
Hydrogen bonds were added where they were observed in the
peptide structures. Long-range constraints (see Table 1) from
independent experiments on intact dark-adapted rhodopsin
were added. The 11-cis retinal was constrained by the solid
state NMR data of Grobner et al. [76]. The construct with the
distance constraints was subjected to simulated annealing
(1000 fs at 1000 K followed by 1500 fs cooling to 200 K). As
a refinement process, additional hydrogen bonds were added
to the constraints when helices became distorted from the
original peptide structures by simulated annealing of the
whole construct, and additional cycles of simulated annealing
were subsequently performed.
The result is a compact structure, strictly from exper-
imental data (no modeling), showing a bundle of seven
helices connected by six turns (Fig. 3) [31]. Superposition of
this structure on the previously published crystal structure of
rhodopsin [30] shows good agreement with the crystal
structure in the transmembrane region.
This structure is consistent with information from other
experiments for dark-adapted rhodopsin (that were not used
in the structure determination). CD data suggested that 60%
of the sequence was helical, in good agreement with 64% in
this structure [35]. Indirect measurements with spin labels
on the intact protein predicted the termination of helix 5
within one residue of that found in this structure [48]. The
inferred termination of the seventh transmembrane helix
from similar measurements [135] agrees within one residue
with this structure. The short anti-parallel h-strands in the
carboxyl terminus of this structure agree with FTIR data on
the intact protein [36]. Specific interactions between resi-
dues 338 and 242 indicate defined structure in the carboxyl
terminus [53]. The third cytoplasmic loop projects towards
the carboxyl terminus in agreement with AFM data [136].
One significant difference between the crystal structure
and the structure derived from the NMR data is found in the
carboxyl terminus. In the former structure, the region of
residues 311–321 is in an a-helix called helix 8 [30]. In the
latter structure, this region is a loop, indicating that there is
little intrinsic tendency (from the primary sequence) to form
a helix in this region. Therefore in rhodopsin the formation
of the helix may well be dependent on an interface; i.e., the
lipid bilayer. These observations could be important to
structure and function in this protein.
8. Structure of metarhodopsin II
The structure just described is the structure of this
receptor in the dark-adapted state. To understand how this
receptor system operates, information on the structure of the
active state is required. Of the several intermediates in the
photocycle, metarhodopsin II (Meta II) is the intermediate
which is responsible for binding and activating the G
protein, transducin. Therefore, the structure of this inter-
mediate is critical to understanding the mechanism of signal
transduction with this receptor system.
Meta II is a transient species. However, it is possible to
trap this species by lowering the temperature. With this
approach, Hubbell and Khorana were able to use site-
directed spin labeling to obtain distance information
between specific sites in the protein while it was in the
Meta II state. These data are analogous to the data used (see
above) to build the tertiary structure of dark-adapted rho-
dopsin. Oprian et al. have found that some of their engi-
neered disulfide bonds do not inhibit the transition from
dark-adapted rhodopsin to Meta II, suggesting that the close
contacts, implied by the disulfide bond formation, are
preserved in the active state. These data provide additional
distance constraints for the active state. These long-range
distance constraints include a contact between the h-ionone
ring of the retinal and A169 of helix 4 [75].
The structure of the dark-adapted state of rhodopsin was
used as the starting point for this structure determination of
Meta II. All the long-range interactions specific for the dark-
adapted structure were removed and the long-range interac-
tions specific for Meta II were added. Simulated annealing
was once again used to fold a structure consistent with the
new data set of experimental long-range distance constraints.
The resulting medium-resolution structure of Meta II is
shown in Fig. 4A. More experimental long-range distance
constraints are available for the cytoplasmic face than for
other parts of the structure. Therefore, the organization of this
region is better defined than other regions of the protein.
Significant structural changes occur upon conversion of
dark-adapted rhodopsin to Meta II. The second and third
cytoplasmic loops move apart and change their conforma-
tion. Upon formation of Meta II, a basic groove opens in the
cytoplasmic face of the receptor, exposing a surface that is
occluded in the dark-adapted state. Exposure of this new
basic surface is likely the signal for G protein binding, since
the face of transducin that binds to rhodopsin is acidic [137].
The precise surface for docking is not known. However, the
likely binding site for transducin can now be mapped on the
cytoplasmic face of Meta II using sequences of peptides that
inhibit the interaction between the receptor and transducin
[126,138,139]. This mapping suggests contact between the
G protein and the groove on the surface of the receptor that
is opened upon the formation of Meta II. The most specific
recent work is that reporting chemical cross-links between
sites on the receptor and sites on transducin that occur in the
complex between transducin and Meta II [140,141]. These
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studies show that in the complex, the N- and C-termini of
transducin a are near the third cytoplasmic loop of Meta II.
These cross-linking data and the structure of Meta II suggest
that the acidic portion of the amino terminal helix of
transducin a (see GRASP picture of transducin Ref.
[137]) may lie in the basic groove on the receptor when
the G protein is bound to Meta II.
The structure of Meta II explains some previously pub-
lished experiments that concern the cytoplasmic face of this
receptor. First, the alteration in cytoplasmic loops 2 and 3
may have been detected previously. These loops contain h-
turns [119] and previous FTIR data suggests a change in h-
turns in the conformation change from rhodopsin to meta-
rhodopsin II [142]. Second, both the crystal structure and the
NMR structure of rhodopsin [30,31] show interactions
between R135 and E134 and E247. The structure of Meta
II shows that upon activation of rhodopsin, the interaction
between R135 and E247 is broken due to the conformational
change. This disruption of interactions between R135 and
E247 was predicted previously for the corresponding resi-
dues in other receptors in the same GPCR family [143,144].
The transmembrane region is defined by fewer experi-
mental long-range distance constraints than are available for
the cytoplasmic face. However, the arrangement of much of
the helical bundle is locked by recent experimental data [66].
These data indicate that the arrangement of helices 1, 2, 5 and
7 is not changed upon conversion of rhodopsin to Meta II.
However, helices 3, 4 and 6move relative to their positions in
the rhodopsin structure, and alter in particular the positions of
the helices in the cytoplasmic face of the receptor. Specifi-
cally, during the photoactivation and the cis– trans isomer-
ization of retinal chromophore, helix 3 is forced outwards
probably as a result of the steric interaction between C9
methyl group of the chromophore and residues on helix 3.
Within the constraints imposed by the work of Struthers et al.
[66], an inward movement of helix 4 is necessary to counter-
act the outward movement of helix 3. During this cooperative
rearrangement, helix 4 is rotated, with A169 coming in close
range to the retinal h-ionone ring. The model of Baldwin
[145] predicts that helix 4 would be capable of rotation since
it does not have a side restricted to interaction with other
members of the helical bundle by the polarity.
This helical arrangement is consistent with predictions
from previous work. For example, the movement of helices 3
and 4 allow a contact in Meta II between the h-ionone ring of
the retinal and A169 of helix 4 as described previously [75].
Research conducted with ring-constrained retinal analogs
suggests that the retinal undergoes a twist when photoisome-
rization takes place, which would force a change in orienta-
tion of the h-ionone ring [77]. The h-ionone ring contacts
helix 3, and thus a change in the orientation of this ring could
induce an alteration in the organization of the transmembrane
helices. Those authors suggest an initial movement of helix 3.
Such a movement was predicted previously to disrupt
restraining interactions that stabilize the inactive state of
another receptor in the same family [146]. Helix 6 also moves
in this structure of Meta II compared to dark-adapted rhodop-
sin, and the distance between the cytoplasmic ends of helix 3
and helix 6 increases, as suggested previously [49,147].
Consequently, the cross-sectional area of the molecule on
the cytoplasmic side increases modestly in the structure of
Meta II compared to dark-adapted rhodopsin, consistent with
an expansion of the receptor upon activation [148].
9. Rhodopsin stability
The structures of integral membrane proteins must
accommodate interactions with two different environments,
the hydrocarbon core of the lipid bilayer in which they are
imbedded and the aqueous phase into which they protrude.
There is a paucity of studies on the stability of membrane
proteins. However, the protein regions that interact with the
aqueous phase seem to behave in a manner similar to
soluble proteins while those within the hydrophobic core
are more structurally stable [149,150]. For example, the two
CD transitions exhibited by cytochrome b5 were interpreted
to represent the aqueous and transmembrane domains [151].
For membrane proteins that traverse the bilayer multiple
times, the relative importance of the extramembraneous
regions and intramembraneous regions to overall protein
stability poses an interesting problem. The complexity of
Fig. 4. (A) GRASP picture of the cytoplasmic face of metarhodopsin II
(1ln6) [170]. The structure was determined as described in the text. The
blue color represents regions of positive charge, and the red color represents
regions of negative charge. (B) Comparison of the structure of dark-adapted
rhodopsin with light-activated rhodopsin (metarhodopsin II), showing the
opening of the surface of the receptor upon activation (see text). The atoms
are colored by type.
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this was demonstrated for bacteriorhodopsin. As stated
earlier, some of the helices of bacteriorhodopsin will asso-
ciate properly without covalently linked loop regions
[152,153]. This suggests that the loops may not be impor-
tant in the stability. However, based on thermal denaturation
studies, it was calculated that loss of all loops would lead to
instability of bacteriorhodopsin at room temperature [152].
The thermal denaturation of rhodopsin is likely to involve
multiple steps including isomerization of 11-cis retinal,
unfolding of regions exposed to the aqueous media and/or
reorientation of the helices. Because opsin does not have 11-
cis retinal, its denaturation would only involve the later two.
Differential scanning calorimetry (DSC) has proven to be a
useful tool in investigating the thermal stability of rhodopsin
in native disk membranes [154–157] and in disk membranes
with altered lipid compositions [158,159]. Interpretation of
these studies is complicated by the irreversible nature of the
denaturation. However, they showed that both the chromo-
phore and the lipid bilayer effect the transition temperature of
rhodopsin denaturation.
Investigations of the scan rate dependence of the calori-
metric transition temperature indicated that at the transition
temperature there is significant formation of the final,
irreversibly denatured species [154,157]. Thus the formation
of irreversibly denatured rhodopsin is rapid in comparison
to reversible processes. The observed asymmetry of the
calorimetric transition is also consistent with this interpre-
tation. The denaturation process of rhodopsin is therefore
subject to kinetic constraints. These constraints may also be
important factors in the stability of cytochrome c oxidase
[160], bacteriorhodopsin [161] and the GLUT 1 receptor
[162]. These studies suggest that rhodopsin may have a
finite, kinetically determined lifetime as a native protein in
the membrane. This observation may be important in
relation to the transit time of disks in the ROS from the
point of biogenesis at the base of the outer segment to the
apical tip of the outer segment.
DSC was also used to investigate the relationship of
rhodopsin cytoplasmic loops to stability and to begin to relate
structural features with rhodopsin stability [157]. Studies of
the papain and chymotrypsin proteolytic fragments (loops 3,
and both 2 and 3 cleaved, respectively), showed that in the
presence of 11-cis retinal, the interaction of the helices is
sufficiently strong such that the complex denatures as a single
unit even though somewhat less energy is required. These
studies were also consistent with the involvement of a
conformational change in the third loop during the transition
to the denatured state. Unlike the case for the unbleached
samples or for the bleached papain fragments, the thermal
denaturation of bleached chymotrypsin fragments produced
two calorimetric transitions. This suggests that the second
cytoplasmic loop may be involved in maintaining the rela-
tionship between helix 3 and helix 4 in the bundle of helices,
and thus their interactions with other helices of the bundle.
When loop 2 is proteolyzed and 11-cis retinal is not exerting a
stabilizing interaction with the adjacent helices, the appro-
priate orientation of helices 3 and 4 may be lost. This could
reduce the helix–helix interactions sufficiently to enable two
sets of helices to denature independently.
10. Lipid–rhodopsin interactions in the disk membrane
Rhodopsin is an integral membrane protein, with much of
its mass buried in the lipid bilayer. Therefore, the interactions
between the lipid and the protein may be important to protein
structure and function. This subject requires considerably
more investigation. Nevertheless, some structural studies
have been reported on the interaction of the lipid component
with rhodopsin in the disk membrane. 31P NMR experiments
have revealed that in the disk membrane about 15–20 of the
phospholipids are interacting significantly with the protein,
perhaps binding to sites on the protein [163]. Chemical
labeling experiments have shown that some of the phospha-
tidylserine in the membrane is protected by protein from
labeling [164]. Some of the phospholipid in the membrane is
protected from phospholipase action; that protected phos-
pholipid component is enriched in phosphatidylserine [165].
These studies collectively suggest that a subset of the phos-
pholipids of the membrane may be binding to rhodopsin and
perhaps modulating its structure and function. Therefore,
future studies should examine in more detail where on
rhodopsin such lipid–protein interactions might have impact.
Biochemical studies have examined in some detail the
influence of the lipid environment on rhodopsin function.
Membrane cholesterol significantly inhibits rhodopsin func-
tion [8,9]. Highly unsaturated phospholipids enhance the
activation of rhodopsin to metarhodopsin II [166]. It has
now been clearly shown that this modulation is propagated
through the structure and dynamics of the lipid bilayer.
Recent studies suggest that polyunsaturated phospholipids
partition directly into the lipid–protein interface, preferen-
tially to other phospholipid species in the disk membrane
[159]. Other studies have suggested that one molecule of
cholesterol may also bind to the surface of rhodopsin within
the membrane at a site with structural specificity for choles-
terol [167].
With the new structural information, these studies on
lipid–protein interactions need to be expanded. Questions
of how and where the lipids interact with the protein, and in
particular, what effects the various lipid components may
have on protein structure, function and stability are now
very important questions that need to be addressed.
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